OMS721

BIOLOGICAL3 trials

Sponsors

Omeros Corporation, Michal Nowicki

Conditions

IgA NephropathyThrombotic MicroangiopathiesThrombotic Microangiopathy

Phase 2

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

CompletedNCT02222545

Omeros CorporationThrombotic Microangiopathies

Start: 2014-11-02End: 2020-08-11Updated: 2024-08-28

Phase 3

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

TerminatedNCT03608033

Omeros CorporationIgA Nephropathy

Start: 2018-04-05End: 2024-01-12Updated: 2025-12-09

Unknown Phase

OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy

Michal NowickiThrombotic Microangiopathy

Updated: 2015-04-15

Related Papers

Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.

2026-01-011 citations

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

2023-02-0940 citations

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the Masp-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Blood2022-11-151 citations

How I Treat IgA Nephropathy

Clinical Journal of the American Society of Nephrology2022-06-0814 citations

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy

Journal of Clinical Oncology2022-04-1987 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis

The Nephron journals/Nephron journals2020-01-0123 citations